alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 31.2
Certification
I, Charles R. Bearchell, certify that
1. I have reviewed this quarterly report on Form 10-Q of Youbet.com, Inc.; 2. Based on my knowledge, this quarterly report does not contain anyuntrue statement of amaterial fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by thisquarterly report; 3. Based on my knowledge, the financial statements, and other financialinformation includedin this quarterly report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this quarterly report. 4. The registrant’s other certifying officer and I are responsible forestablishing andmaintaining disclosure controls and procedures (as defined in Exchange ActRules 13a-15(e) and 15d-15(e)) [omitted in accordance with Section III.E.of SEC Release No. 34-47986] for the registrant and we have:
a. designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made known tous by others within those entities, particularly during the period inwhich this quarterly report is being prepared; b. [Omitted in accordance with Section III.E. of SEC Release No.34-47986.] c. evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures, asof the end of the period covered by this report based on suchevaluation; and d. disclosed, if applicable, in this quarterly report any change inthe registrant’s internalcontrol over financial reporting that occurred during the quartercovered by the report that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control overfinancial reporting; and
5. The registrant’s other certifying officer and I have disclosed, basedon our most recentevaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of registrant’s board ofdirectors (or persons performing the equivalent function):
a. all significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reporting whichare reasonably likely to adversely affect the registrant’s ability torecord, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’sinternal controls over financial reporting.       August 13, 2004 By: /s/ Charles R. Bearchell     Charles R. Bearchell     Chief Financial Officer
39164.

#### JOHNSON v. PIONEER FINANCE COMPANY.

Nichols, Presiding Judge.

1. “ ‘An exception to the refusal of the trial court to award a nonsuit will not be considered where the case resulted in a verdict for the plaintiff, and a motion for new trial was denied on the ground that the verdict was contrary to the evidence and without evidence to support it.’ *[Guarantee Trust Life Ins. Co. v. Hill,*90 Ga. App. 297 (3), 82 SE2d 885].” *Reserve Ins. Co. v. Foster,*96 Ga. App. 337, 340 (99 SE2d 839). Accordingly, special ground 4 of the amended motion for new trial which assigns error on the refusal to grant a nonsuit cannot be considered where the defendant has sought a new trial on the usual general grounds.

*821Decided November 20, 1961.

2. “A ground of a motion for a new trial, complaining of the admission of documentary evidence, that does not set out literally or in substance or attach as an exhibit the document objected to, or does not point out in such ground such parts of the record by page number as are necessary to an understanding of the errors complained of, is not in proper form and is incomplete to raise any question for decision.” *Maxwell v. Hollis,*214 Ga. 358 (1) (104 SE2d 893). Accordingly, the remaining special grounds of the defendant’s amended motion for new trial which assign error on the admission of certain documentary evidence but failed to set forth such evidence or to refer to such evidence by page number are incomplete and cannot be considered.

3. The evidence on the trial of the case, an action in trover to recover a house trailer, disclosed that the defendant had purchased a house trailer from R. Edwards & Sons Trailer Sales on June 6, 1960, that a conditional-sale contract on such trailer was transferred to the plaintiff on the same day, that the serial number contained on such bill of sale was the same as the one on the trailer claimed by the defendant to be a different trailer although there was a discrepancy in the year model (1957 or 1958), that the defendant had made only one payment to the plaintiff and was in arrears on such payments, that the plaintiff had authorized its agent to collect the amount due, and past due, on such account or repossess the trailer covered by such conditional-sale contract, and that the agent contacted the defendant who referred him to his attorney. Neither the plaintiff nor the defendant introduced any evidence of an actual demand by the plaintiff or its agent on the defendant for possession of the property covered by the conditional-sale contract. Since a demand and refusal is necessary to show the conversion of a chattel delivered to a vendee under a conditional-sale contract before trover will lie *(Robbins v. Welfare Finance Corp.,*95 Ga. App. 90, 96 SE2d 892), the evidence did not authorize the judgment for the plaintiff by the court sitting without the intervention of a jury, and the trial court erred in overruling the defendant’s motion for a new trial on the usual general grounds.

*Judgment reversed.*

*Frankum cmd Jordan, JJ., concur.*

*822
      *Philip T. Keen, Franklin B. Anderson,*for plaintiff in error.

*Preston L. Holland,*contra.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM GULFWEST
OIL COMPANY'S QUARTERLY REPORT FILED ON FORM 10-Q FOR THE QUARTER ENDED
SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL DOCUMENTS.
</LEGEND>
<CIK>                         0000813779
<NAME>                        0
<MULTIPLIER>                  1
<CURRENCY>                    0

<S>                          <C>
<PERIOD-TYPE>                 9-MOS
<FISCAL-YEAR-END>             DEC-31-1999
<PERIOD-START>                JAN-01-2000
<PERIOD-END>                  SEP-30-2000
<EXCHANGE-RATE>               1
<CASH>                        30,740
<SECURITIES>                  0
<RECEIVABLES>                 1,981,487
<ALLOWANCES>                  0
<INVENTORY>                   0
<CURRENT-ASSETS>              2,144,499
<PP&E>                        27,780,320
<DEPRECIATION>                3,542,051
<TOTAL-ASSETS>                26,986,930
<CURRENT-LIABILITIES>         6,797,444
<BONDS>                       0
<PREFERRED-MANDATORY>         0
<PREFERRED>                   80
<COMMON>                      18,445
<OTHER-SE>                    6,504,945
<TOTAL-LIABILITY-AND-EQUITY>  26,986,930
<SALES>                       2,173,680
<TOTAL-REVENUES>              2,291,848
<CGS>                         0
<TOTAL-COSTS>                 1,547,051
<OTHER-EXPENSES>              0
<LOSS-PROVISION>              0
<INTEREST-EXPENSE>            605,250
<INCOME-PRETAX>               140,363
<INCOME-TAX>                  0
<INCOME-CONTINUING>           140,363
<DISCONTINUED>                0
<EXTRAORDINARY>               0
<CHANGES>                     0
<NET-INCOME>                  140,363
<EPS-BASIC>                   .01
<EPS-DILUTED>                 .01




</TABLE>
§ 56.104 Exemptions from IRB requirement. The following categories of clinical investigations are exempt from the requirements of this part for IRB review: ( a ) Any investigation which commenced before July 27, 1981 and was subject to requirements for IRB review under FDA regulations before that date, provided that the investigation remains subject to review of an IRB which meets the FDA requirements in effect before July 27, 1981.
( b ) Any investigation commenced before July 27, 1981 and was not otherwise subject to requirements for IRB review under Food and Drug Administration regulations before that date.
( c ) Emergency use of a test article, provided that such emergency use is reported to the IRB within 5 working days. Any subsequent use of the test article at the institution is subject to IRB review.
( d ) Taste and food quality evaluations and consumer acceptance studies, if wholesome foods without additives are consumed or if a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural, chemical, or environmental contaminant at or below the level found to be safe, by the Food and Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture.
[46 FR 8975, Jan. 27, 1981, as amended at 56 FR 28028, June 18, 1991]
§ 803.58 Foreign manufacturers. ( a ) Every foreign manufacturer whose devices are distributed in the United States shall designate a U.S. agent to be responsible for reporting in accordance with § 807.40 of this chapter. The U.S. designated agent accepts responsibility for the duties that such designation entails. Upon the effective date of this regulation, foreign manufacturers shall inform FDA, by letter, of the name and address of the U.S. agent designated under this section and § 807.40 of this chapter, and shall update this information as necessary. Such updated information shall be submitted to FDA, within 5 days of a change in the designated agent information.
( b ) U.S.-designated agents of foreign manufacturers are required to: ( 1 ) Report to FDA in accordance with §§ 803.50, 803.52, 803.53, and 803.56;
( 2 ) Conduct, or obtain from the foreign manufacturer the necessary information regarding, the investigation and evaluation of the event to comport with the requirements of § 803.50;
( 3 ) Forward MDR complaints to the foreign manufacturer and maintain documentation of this requirement;
( 4 ) Maintain complaint files in accordance with § 803.18; and
( 5 ) Register, list, and submit premarket notifications in accordance with part 807 of this chapter.
Effective Date Note
Effective Date Note: At 79 FR 8846, Feb. 14, 2014, part 803 was revised. At 79 FR 8855, Feb. 14, 2014, § 803.58 was stayed indefinitely.
Exhibit














FOX FACTORY HOLDING CORP.
2013 OMNIBUS PLAN


Amendment to Restricted Stock Unit Award Agreement 




WHEREAS, by a Restricted Stock Unit Award Agreement effective as of May 5, 2016 (the “Agreement”), Fox Factory Holding Corp., a Delaware corporation (“Fox Factory” or “Company”) granted to Joseph Hagin (the “Participant”) a Restricted Stock Unit Award consisting of the right to earn an aggregate of 2,303 shares of common stock, par value $0.001 per share, of the Company subject to the terms and conditions set forth in the Agreement. 
WHEREAS, the Company and the Participant desire to amend the Agreement to accelerate the vesting of the Award.
NOW, THEREFORE, effective January 11, 2017, the definition of “Performance Period” shall be amended in its entirety to provide as follows:
“May 5, 2016 through January 11, 2017”
FURTHER, effective January 11, 2017, Section 2(b) of the Agreement shall be amended in its entirety to provide as follows:
“(b) Subject to the terms of this Agreement and those of the Plan, this Award shall vest on January 11, 2017; provided that the Participant’s service as a Director of the Company has not ceased before the particular vesting date. Notwithstanding the foregoing, this Award shall vest with respect to all of the Shares, upon the occurrence of the death of the Participant or a Change of Control of the Company; provided in each case that the Participant’s service with the Company has not ceased before the date of the occurrence of such event.”




	
		
	FOX FACTORY HOLDING CORP.




By:/s/ Larry L. Enterline 


Title:CEO


Date:1/11/2017
	PARTICIPANT




/s/ Joseph Hagin 
Joseph Hagin


Date:  1/10/2017
#### § 20.27 Submission of records marked as confidential.

Marking records submitted to the Food and Drug Administration as confidential, or with any other similar term, raises no obligation by the Food and Drug Administration to regard such records as confidential, to return them to the person who has submitted them, to withhold them from disclosure to the public, or to advise the person submitting them when a request for their public disclosure is received or when they are in fact disclosed.

[42 FR 15616, Mar. 22, 1977, as amended at 68 FR 25285, May 12, 2003]
[Federal Register Volume 75, Number 40 (Tuesday, March 2, 2010)]
[Notices]
[Pages 9414-9415]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4227]


-----------------------------------------------------------------------

FEDERAL RESERVE SYSTEM


Formations of, Acquisitions by, and Mergers of Bank Holding 
Companies

    The companies listed in this notice have applied to the Board for 
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 
1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other 
applicable statutes and regulations to become a bank holding company 
and/or to acquire the assets or the ownership of, control of, or the 
power to vote shares of a bank or bank holding company and all of the 
banks and nonbanking companies owned by the bank holding company, 
including the companies listed below.
    The applications listed below, as well as other related filings 
required by the Board, are available for immediate inspection at the 
Federal Reserve Bank indicated. The applications also will be available 
for inspection at the offices of

[[Page 9415]]

the Board of Governors. Interested persons may express their views in 
writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). 
If the proposal also involves the acquisition of a nonbanking company, 
the review also includes whether the acquisition of the nonbanking 
company complies with the standards in section 4 of the BHC Act (12 
U.S.C. 1843). Unless otherwise noted, nonbanking activities will be 
conducted throughout the United States. Additional information on all 
bank holding companies may be obtained from the National Information 
Center website at www.ffiec.gov/nic/.
    Unless otherwise noted, comments regarding each of these 
applications must be received at the Reserve Bank indicated or the 
offices of the Board of Governors not later than March 26, 2010.
    A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant 
Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:
    1. Platte Valley Bancorp, Inc., to become a bank holding company by 
acquiring 100 percent of the voting shares of Platte Valley Bank, both 
of North Bend, Nebraska.
    B. Federal Reserve Bank of San Francisco (Kenneth Binning, Vice 
President, Applications and Enforcement) 101 Market Street, San 
Francisco, California 94105-1579:
    1. Franklin Resources, Inc., San Mateo, California; to retain 9.53 
percent of the voting shares of West Coast Bancorp, and thereby 
indirectly retain voting shares of West Coast Bank, both of Lake 
Oswego, Oregon.

    Board of Governors of the Federal Reserve System, February 25, 
2010.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2010-4227 Filed 3-1-10; 8:45 am]
BILLING CODE 6210-01-S
§ 522.770 Doramectin. ( a ) *Specifications.* Each milliliter of solution contains 10 milligrams of doramectin.
( b ) *Sponsors.* See Nos. 054771 and 069043 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.222 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Cattle* — ( i ) *Amount.* 200 micrograms per kilogram (10 milligrams per 110 pounds).
( ii ) *Indications for use.* For treatment and control of gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice, and mange mites. To control infections and to protect from reinfection with *Cooperia oncophora* and *Haemonchus placei* for 14 days, *Ostertagia ostertagi* for 21 days, and *C. punctata, Oesophagostomum radiatum,* and *Dictyocaulus viviparus* for 28 days after treatment.
( iii ) *Limitations.* Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. Administer as a single subcutaneous or intramuscular injection. Do not slaughter cattle for human consumption within 35 days of treatment. Not for use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
( 2 ) *Swine* — ( i ) *Amount.* 300 micrograms per kilogram (10 milligrams per 75 pounds).
( ii ) *Indications for use.* For treatment and control of gastrointestinal roundworms, lungworms, kidney worms, sucking lice, and mange mites.
( iii ) *Limitations.* Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. Administer as a single intramuscular injection. Do not slaughter swine for human consumption within 24 days of treatment.
[61 FR 53321, Oct. 11, 1996, as amended at 62 FR 44410, Aug. 21, 1997; 62 FR 62242, Nov. 21, 1997; 63 FR 68183, Dec. 10, 1998; 64 FR 13509, Mar. 19, 1999; 79 FR 16187, Mar. 25, 2014; 84 FR 32992, July 11, 2019; 88 FR 55564, Aug. 16, 2023]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Homeland Security

###### Federal Emergency Management Agency

          - [Internal Agency Docket No. FEMA-3308-EM; Docket ID FEMA-2010-0002]

# AGENCY:

Federal Emergency Management Agency, DHS.

# ACTION:

Notice.

# SUMMARY:

This notice amends the notice of an emergency declaration for the State of Oklahoma (FEMA-3308-EM), dated January, 30, 2010, and related determinations.

# DATES:

*Effective Date:*                         January, 30, 2010.                    

# FOR FURTHER INFORMATION CONTACT:

Peggy Miller, Disaster Assistance Directorate, Federal Emergency Management Agency, 500 C Street, SW., Washington, DC 20472, (202) 646-3886.

# SUPPLEMENTARY INFORMATION:

Notice is hereby given that the incident period for this emergency is closed effective January, 30, 2010.

The following Catalog of Federal Domestic Assistance Numbers (CFDA) are to be used for reporting and drawing funds: 97.030, Community Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis Counseling; 97.033, Disaster Legal Services; 97.034, Disaster Unemployment Assistance (DUA); 97.046, Fire Management Assistance Grant; 97.048, Disaster Housing Assistance to Individuals and Households In Presidentially Declared Disaster Areas; 97.049, Presidentially Declared Disaster Assistance—Disaster Housing Operations for Individuals and Households; 97.050, Presidentially Declared Disaster Assistance to Individuals and Households—Other Needs; 97.036, Disaster Grants—Public Assistance (Presidentially Declared Disasters); 97.039, Hazard Mitigation Grant.

W. Craig Fugate,

Administrator, Federal Emergency Management Agency.

[FR Doc. 2010-4223 Filed 3-1-10; 8:45 am]

BILLING CODE 9111-23-P
# C_2016111EN.01002001.xml

| 29.3.2016 | EN | Official Journal of the European Union | C 111/20 |
| --- | --- | --- | --- |

29.3.2016

EN

Official Journal of the European Union

C 111/20

---

Judgment of the General Court of 18 February 2016 — Calberson GE v Commission

(Case T-164/14) (1)

1

((Arbitration clause - Programme to supply agricultural products to Russia - Supply of beef - Non-performance of the contract by the intervention agency - Applicable law - Limitation - Late release of certain supply securities - Partial payment of a transport invoice - Underpayment in foreign currency of certain invoices - Default interest))

(2016/C 111/24)

Language of the case: French

Parties

Parties

Applicant: Calberson GE (Villeneuve-Garenne, France) (represented by: T. Gallois and E. Dereviankine, lawyers)

Applicant:

Defendant: European Commission (represented by: D. Bianchi and I. Galindo Martín, acting as Agents)

Defendant:

Intervener in support of the defendant: French Republic (represented by: D. Colas and C. Candat, acting as Agents)

Intervener in support of the defendant:

Re:

Re:

Application under Article 272 TFEU for an order requiring the Commission to compensate the applicant for the loss which it claims to have suffered following acts of misconduct allegedly committed by the intervention agency in the performance of a contract relating to the transport of beef to Russia in accordance with Commission Regulation (EC) No 111/1999 of 18 January 1999 laying down general rules for the application of Council Regulation (EC) No 2802/98 on a programme to supply agricultural products to the Russian Federation (OJ 1999 L 14, p. 3), and Commission Regulation (EC) No 1799/1999 of 16 August 1999 on the supply of beef to Russia (OJ 1999 L 217, p. 20).

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Calberson GE to pay the costs; |
| --- | --- |

2.

Orders Calberson GE to pay the costs;

| 3. | Orders the French Republic to bear its own costs. |
| --- | --- |

3.

Orders the French Republic to bear its own costs.

---

(1)  OJ C 184, 16.6.2014.

1

---